Literature DB >> 30410291

Results of Ten-Year Follow-Up of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy.

Maksim Kashtanov1, Anastasiya Rzhannikova1,2, Sergey Chernyshev1, Lev Kardapoltsev1, Eduard Idov1,2, Sergey Berdnikov1.   

Abstract

This study looks at 10-year follow-up outcomes of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. Between 2000 and 2008, 40 patients with obstructive hypertrophic cardiomyopathy (27 males, 13 females) underwent alcohol septal ablation. The median follow-up period was 123 (2-179) months. The mean age ran to 43.8 + 13.9 years. The initial dose of ethanol (3 mL) was chosen for ablation in all cases. The hospital mortality was 0%. Permanent pacemakers were implanted in 3 of 40 (7.5%) cases in the hospital period. The median clinical follow-up was 123 (2-179) months. Survival rates at 1, 5, 10, and 15 years after the procedure were as follows: 97.5% (95% confidence interval [CI], 95.1-99.9%), 92.5% (95% CI, 94.8-90.2%), 85.0% (95% CI, 82.9-87.1%), and 81.3% (95% CI, 79.3-83.3%), respectively. Seven patients died during follow-up. Sudden death was observed in two cases. Permanent pacemakers were implanted in 2 of 40 (5%) cases in the follow-up. The log-rank test revealed no statistically significant difference between the 15-year survival rate in our cohort and age- and sex-matched general Russian population ( p  = 0.11113). Alcohol septal ablation provides long-term survival rates that look comparable with age- and sex-matched general population in the 15-year follow-up period.

Entities:  

Keywords:  cardiovascular disease; coronary intervention; endovascular procedure; hemodynamics; infarction; intramyocardial; percutaneous

Year:  2018        PMID: 30410291      PMCID: PMC6221794          DOI: 10.1055/s-0038-1675213

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  15 in total

1.  Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years.

Authors:  Josef Veselka; Pavol Tomašov; David Zemánek
Journal:  Can J Cardiol       Date:  2011-10-14       Impact factor: 5.223

Review 2.  Contemporary techniques for catheter-based intervention for hypertrophic obstructive cardiomyopathy.

Authors:  Thomas Cuisset; Thierry Lefèvre
Journal:  EuroIntervention       Date:  2016-05-17       Impact factor: 6.534

Review 3.  Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients.

Authors:  Barry J Maron; Magdi Yacoub; Joseph A Dearani
Journal:  Eur Heart J       Date:  2011-02-14       Impact factor: 29.983

4.  Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry.

Authors:  Sherif F Nagueh; Bertron M Groves; Leonard Schwartz; Karen M Smith; Andrew Wang; Richard G Bach; Christopher Nielsen; Ferdinand Leya; John M Buergler; Steven K Rowe; Anna Woo; Yolanda Munoz Maldonado; William H Spencer
Journal:  J Am Coll Cardiol       Date:  2011-11-22       Impact factor: 24.094

5.  Effectiveness and safety beyond 10 years of percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  José M de la Torre Hernandez; Monica Masotti Centol; Piedad Lerena Saenz; Ángel Sánchez Recalde; Federico Gimeno de Carlos; Pablo Piñón Esteban; Diego Fernandez Rodriguez; Marta Sitges Carreño; Manel Sabate Tenas; Javier Zueco Gil
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2013-12-04

6.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

7.  Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population.

Authors:  Josef Veselka; Jan Krejčí; Pavol Tomašov; David Zemánek
Journal:  Eur Heart J       Date:  2014-01-24       Impact factor: 29.983

8.  Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Paul Sorajja; Steve R Ommen; David R Holmes; Joseph A Dearani; Charanjit S Rihal; Bernard J Gersh; Ryan J Lennon; Rick A Nishimura
Journal:  Circulation       Date:  2012-10-17       Impact factor: 29.690

9.  Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.

Authors:  Josef Veselka; Morten Kvistholm Jensen; Max Liebregts; Jaroslav Januska; Jan Krejci; Thomas Bartel; Maciej Dabrowski; Peter Riis Hansen; Vibeke Marie Almaas; Hubert Seggewiss; Dieter Horstkotte; Pavol Tomasov; Radka Adlova; Henning Bundgaard; Robbert Steggerda; Jurriën Ten Berg; Lothar Faber
Journal:  Eur Heart J       Date:  2016-01-07       Impact factor: 29.983

10.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

View more
  1 in total

Review 1.  Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Victor Arévalos; Juan José Rodríguez-Arias; Salvatore Brugaletta; Antonio Micari; Francesco Costa; Xavier Freixa; Mónica Masotti; Manel Sabaté; Ander Regueiro
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.